Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $32.5 million.

  • Eton Pharmaceuticals' Non-Current Assets rose 43365.07% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.9 million, marking a year-over-year increase of 46419.94%. This contributed to the annual value of $35.1 million for FY2024, which is 61622.12% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Non-Current Assets of $32.5 million as of Q3 2025, which was up 43365.07% from $33.2 million recorded in Q2 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Non-Current Assets peaked at $35.1 million during Q4 2024, and registered a low of $743000.0 during Q3 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $4.9 million (2023), whereas its average is $10.4 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Non-Current Assets tumbled by 5385.09% in 2021 and then surged by 61622.12% in 2024.
  • Eton Pharmaceuticals' Non-Current Assets (Quarter) stood at $3.9 million in 2021, then soared by 30.17% to $5.0 million in 2022, then dropped by 2.49% to $4.9 million in 2023, then soared by 616.22% to $35.1 million in 2024, then dropped by 7.38% to $32.5 million in 2025.
  • Its Non-Current Assets was $32.5 million in Q3 2025, compared to $33.2 million in Q2 2025 and $34.1 million in Q1 2025.